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1 |  INTRODUCTION
Status epilepticus (SE) affects approximately 41 of every 
100 000 adults and is difficult to treat. For this reason, up 
to 20% of cases are reported to involve mortality.1 Various 
neurological disorders are associated with SE, including 
cerebrovascular diseases, trauma, intoxication, and also oth-
ers, but it is unclear why SE develops only in some patients 
affected by the previously mentioned central nervous sys-
tem (CNS) disorders. In addition, SE also develops without 
a clear reason in some cases. Finally, patients with epilepsy 
may experience one or more episodes of SE, whereas others 
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Abstract
Neurosteroids can modulate γ-aminobutyric acid type A receptor-mediated in-
hibitory currents. Recently, we discovered that the neurosteroids progesterone, 
5α-dihydroprogesterone, allopregnanolone, and pregnanolone are reduced in the cer-
ebrospinal fluid of patients with status epilepticus (SE). However, it is undetermined 
whether neurosteroids influence SE. For this reason, first we evaluated whether the 
inhibitor of adrenocortical steroid production trilostane (50 mg/kg) could modify the 
levels of neurosteroids in the hippocampus and neocortex, and we found a remark-
able increase in pregnenolone, progesterone, 5α-dihydroprogesterone, and allopreg-
nanolone levels using liquid chromatography tandem mass spectrometry. Second, we 
characterized the dynamics of SE in the presence of the varied neurosteroidal milieu 
by a single intraperitoneal kainic acid (KA; 15 mg/kg) injection in trilostane-treated 
rats and their controls. Convulsions started in advance in the trilostane group, already 
appearing 90  minutes after the KA injection. In contrast to controls, convulsions 
prevalently developed as generalized seizures with loss of posture in the trilostane 
group. However, this effect was transient, and convulsions waned 2 hours before the 
control group. Moreover, electrocorticographic traces of convulsions were shorter 
in trilostane-treated rats, especially at the 180-minute (P <  .001) and 210-minute 
(P < .01) time points. These findings indicate that endogenous neurosteroids remark-
ably modulate SE dynamics.
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do not. Presently, the possible factors responsible for this dif-
ferent propensity to develop SE are undetermined.
By characterizing neurosteroid levels in cerebrospinal 
fluid of patients with SE, we found that progesterone, 5α-di-
hydroprogesterone, allopregnanolone, and pregnanolone 
were all significantly reduced in comparison to presumably 
healthy controls.2 All the mentioned neurosteroids are known 
to modulate γ-aminobutyric acid (GABA) type A receptor 
(GABAA) activity, and especially 3α-reduced neurosteroids 
such as allopregnanolone and pregnanolone are potent pos-
itive modulators of GABAA-mediated inhibitory currents.
3 
For this reason, we hypothesized that the changes observed 
in CNS neurosteroid levels could be relevant for SE onset or 
evolution.
On the other hand, the possible role of neurosteroids 
in SE has been questioned by a multicenter trial based on 
treatment with the allopregnanolone analogue brexanolone, 
which failed in demonstrating beneficial effects on the course 
of refractory SE.4 A possible limitation in this study was the 
lack of stimulation of endogenous neurosteroid production, 
because different types of neurosteroids can interact with the 
GABAA receptor. Both allopregnanolone and pregnanolone 
are reduced in patients with SE; therefore, a more general 
approach to increase the overall neurosteroid CNS concentra-
tion should be followed to potentiate the effects of neuroste-
roids on GABAergic function.
To evaluate the possibility of inducing an overall in-
crease of neurosteroid levels in the CNS, we considered the 
3β-hydroxysteroid dehydrogenase/Δ5-4 isomerase inhibitor 
trilostane, which is actually used for treatment of pituitary-de-
pendent hyperadrenocorticism, primary hyperadrenocor-
ticism, and alopecia X in dogs.5 A known consequence of 
trilostane administration is the increase in pregnenolone, al-
lopregnanolone, and allotetrahydrocorticosterone CNS levels 
in castrated rodents.6 This occurs because trilostane blocks 
the conversion of pregnenolone to progesterone in the adre-
nal cortex, inducing an increase in the peripheral synthesis of 
the precursor pregnenolone that, when reaching the brain, is 
then used to boost overall neurosteroid production. Thus, we 
aimed to reproduce the same phenomenon in healthy rats and 
to assess whether the increased availability of neurosteroids 
could affect the course of SE induced by kainic acid (KA) 
administration.
2 |  MATERIALS AND METHODS
2.1 | Animals and treatments
Forty-two adult male Sprague-Dawley rats (Charles River) of 
175- to 200-g body weight were used in this study. All ani-
mals were housed in a specific pathogen–free facility under 
a controlled environment with ad libitum access to water and 
food. Experiments received local approval from the Animal 
Welfare Body, as well from the Italian Ministry of Health 
(544/2020-PR). Studies were conducted in accordance with 
the US Public Health Service's Policy on Humane Care and 
Use of Laboratory Animals. All efforts were made to im-
prove welfare and to reduce the number of animals used for 
experiments.
2.2 | Experimental design
Two different experiments were performed, the first to de-
termine the changes in hippocampal and neocortical levels 
of neurosteroids in naive rats not experiencing the SE, ac-
cording to a previously established protocol of trilostane ad-
ministration,6 and the second to characterize the dynamics 
of KA-induced SE in the presence of the different neuroster-
oid levels determined by trilostane treatment. To this aim, 
trilostane (Cayman Chemical) was dissolved in sesame oil 
and subcutaneously injected (50 mg/kg) 16 and 2 hours be-
fore euthanasia (n = 12, first experiment), or 16 and 2 hours 
before the induction of SE by KA (n  =  9, second experi-
ment). Control rats were also treated with sesame oil 16 and 
2 hours before euthanasia (n = 12, first experiment), or 16 
and 2 hours before the induction of SE (n = 9, second experi-
ment). KA (Sigma-Aldrich) was dissolved in saline and in-
traperitoneally injected (15 mg/kg) as described previously.7
2.3 | Electrode implantation and video-
electrocorticography
We implanted electrodes and obtained video-electrocortico-
graphic (ECoG) recordings from 18 rats belonging to the pre-
viously described groups (vehicle and trilostane) and treated 
with KA (second experiment), starting before the induction 
of SE. The investigators who scored the seizures (C.L. and 
L.S.) were blinded to the treatment received by the ani-
mals. See the Supporting Information Data S1 for a detailed 
description.
2.4 | Quantitative analysis of neurosteroids 
by liquid chromatography–electrospray 
tandem mass spectrometry
See the Supporting Information Data S1.
2.5 | Statistical analysis
Data were analyzed using Sigma Plot 11 (Systat Software). 
Hippocampal and neocortical neurosteroid levels in treatment 
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groups were compared by the Mann-Whitney test. Outliers 
were identified using the Grubbs test and removed before an-
alyzing video-ECoG data using a repeated measure two-way 
analysis of variance, considering time and treatment as the 
between and within factors, respectively. Then, groups were 
compared by post hoc Holm-Šídák test. The area under the 
curve of seizure duration (stage 4 + 5) was compared by the 
Student t test. Results are reported as median and interquar-
tile range, or mean values and standard error of the mean, and 
considered significant when P < .05.
3 |  RESULTS
First, we analyzed the impact of trilostane on brain neuro-
steroid levels. We found that the 3β-hydroxysteroid dehy-
drogenase/Δ5-4 isomerase inhibitor, injected twice before 
euthanasia, induced a remarkable increase in hippocampal 
and neocortical neurosteroid levels. Specifically, pregne-
nolone, progesterone, 5α-dihydroprogesterone, and allo-
pregnanolone were respectively increased to up to 469% 
(P ≤ .001 vs vehicle-treated rats, Mann-Whitney test), 592% 
(P  ≤  .001), 168% (P  <  .05), and 183% (P  <  .01) of con-
trol levels in the hippocampus of trilostane-treated rats; in 
contrast, pregnenolone sulfate and pregnanolone did not 
vary significantly (Table 1). Also in the neocortex, we found 
similar results for almost all the evaluated neurosteroids 
(pregnenolone sulfate,  +123%, P  =  .01 vs vehicle-treated 
rats; pregnenolone, +606%, P ≤ .001; progesterone, +946%, 
P ≤  .001; 5α-dihydroprogesterone, +380%, P ≤  .001; allo-
pregnanolone,  +527%, P  ≤  .001), with the only exception 
being pregnanolone (Table 1).
Second, we characterized the dynamics of SE in the pres-
ence of the modified neurosteroidal milieu. Although we did 
not find any significant difference in the latency to SE onset 
(trilostane-treated rats, 46.67 ± 4.9 minutes; vehicle-treated 
rats, 44.16  ±  7.2  minutes) and the respective SE duration 
(trilostane-treated rats, 9.02 ± 0.5 hours; vehicle-treated rats, 
10.83 ± 0.8 hours), we observed remarkable differences in 
seizures recorded in the course of SE, in both occurrence and 
duration (Figure S1).
Specifically, 90 minutes after the induction of SE, stage 4 
seizures were more frequent in the trilostane group (P < .05 
vs vehicle-treated rats, Holm-Šídák test), reaching the peak 
30  minutes later (2  hours after KA administration) and 
maintaining this high level up to the 150-minute time point 
(Figure 1A). In vehicle-treated rats, stage 4 seizures increased 
60 minutes later, reaching the same level as trilostane-treated 
rats at the 150-minute time point. However, the reduction in 
stage 4 seizures was more rapid in trilostane-treated rats, as 
shown at the 4-hour time point, at which seizures were lower 
in these animals compared to controls (P < .05).
Stage 5 seizures (Figure  1B) also presented accelerated 
development in the same animals, peaking 90 minutes after 
the KA injection (P < .001 vs vehicle-treated rats). Moreover, 
the peak observed in trilostane-treated rats doubled that of 
vehicle-treated rats, in which it appeared at the 3-hour time 
point. After their respective peaks, stage 5 seizures wane fol-
lowing a similar dynamic in both treatment groups.
By considering stage 4 and 5 seizures together 
(Figure 1C), it is possible to observe that convulsive sei-
zures occurred in both treatment groups to the same extent, 
with early increases at 90-120 minutes in trilostane-treated 
rats (respectively, P < .001 and P < .05 vs vehicle-treated 
rats). The peak in the vehicle group instead occurred at the 
T A B L E  1  Tissue levels of various neurosteroids in both hippocampus and neocortex of rats treated with trilostane and their respective 
controls
Analytes, ng/mg Vehicle Trilostane Statistics
Pregnenolone sulfate, hippocampus 0.000529 (0.00043-0.00055) 0.000513 (0.00043-0.00058) NS
Pregnenolone sulfate, neocortex 0.000195 (0.000190-0.000225) 0.000240 (0.000220-0.000305) P = .010
Pregnenolone, hippocampus 0.0160 (0.014-0.022) 0.0751 (0.033-0.137) P ≤ .001
Pregnenolone, neocortex 0.017 (0.0164-0.0208) 0.103 (0.0422-0.145) P ≤ .001
Progesterone, hippocampus 0.00066 (0.000599-0.000798) 0.00391 (0.0019-0.0072) P ≤ .001
Progesterone, neocortex 0.00048 (0.00038-0.00073) 0.00454 (0.0019-0.0072) P ≤ .001
5α-Dihydroprogesterone, 
hippocampus
0.000411 (0.00037-0.00045) 0.000691 (0.00046-0.00078) P < .05
5α-Dihydroprogesterone, neocortex 0.000175 (0.000155-0.000205) 0.000665 (0.000335-0.000828) P ≤ .001
Allopregnanolone, hippocampus 0.000253 (0.000169-0.000312) 0.000464 (0.000310-0.000576) P < .01
Allopregnanolone, neocortex 0.000091 (0.00008-0.00013) 0.000480 (0.000245-0.000732) P ≤ .001
Pregnanolone, hippocampus 0.000216 (0.000175-0.000283) 0.000197 (0.000155-0.000251) NS
Pregnanolone, neocortex 0.0000857 (0.0000763-0.0000912) 0.0000824 (0.000064-0.000101) NS
Note: Results are presented as median and interquartile range. Values were compared by the Mann-Whitney test.
Abbreviation: NS, not significant.
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150-minute time point. Subsequently, convulsive seizures 
similarly decreased in both groups, almost disappearing 
7 hours after KA administration.
Then, we evaluated the duration of convulsive seizures 
over time. Interestingly, stage 4 seizures had a longer du-
ration in vehicle-treated rats (Figure 1D), starting from the 
150-minute time point (P < .05 vs trilostane-treated rats) up 
to the 330-minute time point (P < .001 vs trilostane-treated 
rats at 180-210 minutes; P < .05 at 300-330 minutes) with 
the exception of the 240- to 270-minute time point. The 
same peak of stage 4 seizure duration observed in vehi-
cle-treated rats was never reached in trilostane-treated 
animals.
Consistently, stage 5 seizures also appeared to be more 
durable in vehicle-treated rats compared to trilostane-treated 
rats 3 hours after KA administration (P < .001, Figure 1E). 
In the vehicle group, duration of stage 5 seizures evaluated 
at its peak doubled that of trilostane-treated rats. However, 
in the following time point duration of stage 5 seizures was 
comparable in both treatment groups.
When stage 4 and stage 5 convulsive seizures were aver-
aged, duration of convulsive seizures was significantly lower 
in rats treated with trilostane at the 180-minute (P < .001 vs 
vehicle-treated rats) and 210-minute (P  <  .05) time points 
(Figure 1F). Additionally, by considering the area under the 
curve for each rat of both groups, we found a remarkable 
2.5-fold difference in the overall seizure duration, which was 
1 666 171.11 ± 476 331.82 seconds2 in vehicle-treated rats 
versus 657 987.75 ± 155 321.00 seconds2 in trilostane-treated 
rats (P = .038, Student t test).
F I G U R E  1  Occurrence and duration of video-recorded seizures during kainic acid (KA)-induced status epilepticus (SE). A-C, Seizures 
induced by KA were counted every 30 minutes for 12 hours. A, Note that stage (st.) 4 seizures increased early (*P < .05 vs vehicle-treated rats, 
Holm-Šídák test) in the trilostane group 90 minutes after induction of SE. Conversely, 150 minutes later these seizures were remarkably reduced 
in the same group (*P < .05 vs vehicle-treated rats). B, Stage 5 seizures also developed precociously in trilostane-treated rats, peaking at the 
90-minute time point (°P < .001 vs vehicle-treated rats, Holm-Šídák test). C, The average occurrence of stage 4 and 5 seizures was respectively 
reached at 90 minutes (°P < .001 vs vehicle-treated rats) and 120 minutes (*P < .05) in trilostane-treated rats. D-F, Duration of convulsive seizures 
over time. D, Interestingly, stage 4 seizures presented longer duration in vehicle-treated rats (150 minutes, *P < .05; 180 minutes, °P < .001; 
210 minutes, °P < .001; 300 minutes, *P < .05; 330 minutes, *P < .05 vs trilostane-treated rats, Holm-Šídák test). E, In contrast, stage 5 seizures 
were longer in the vehicle-treated group only at the 180-minute time point (°P < .001). F, Considering stage 4 and stage 5 convulsive seizures 
together, rats treated with trilostane presented a significant reduction in seizure duration at the 180-minute (°P < .001) and 210-minute (*P < .05) 
time points
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4 |  DISCUSSION
Our purpose was to describe the development of SE in the 
presence of altered neurosteroid levels in the brain. For this 
reason, first we evaluated the effects of trilostane adminis-
tration on neocortical and hippocampal neurosteroid levels. 
Trilostane is an inhibitor of 3β-hydroxysteroid dehydroge-
nase/Δ5-4 isomerase that was developed as a cancer drug for 
humans, then used to reduce hyperadrenocorticism in dogs. 
Specifically, trilostane blocks corticosterone synthesis and 
removes the inhibitory control of adrenocorticotropic hor-
mone (ACTH), leading to enhanced stimulatory drive on 
adrenocortical activity. Thus, ACTH stimulates the con-
version of cholesterol to pregnenolone and overcomes the 
block of 3β-hydroxysteroid dehydrogenase/Δ5-4 isomerase 
to restore corticosterone production and to increase the 
availability of the neurosteroid precursor pregnenolone.8 
A previous investigation in castrated mice showed that 
trilostane increases levels of pregnenolone and allopreg-
nanolone in the CNS,9 similarly to our results. In the same 
work, trilostane also induced a remarkable increase in al-
lotetrahydrocorticosterone, which was not measured in our 
animals.
The changes in CNS neurosteroid levels we found in tri-
lostane-treated rats resulted in remarkable effects on the dy-
namics of SE induced by KA. Although the latency to SE 
onset was not affected, trilostane-treated rats anticipated the 
occurrence of convulsive seizures in response to KA. The 
most severe stage 5 seizures were also more frequent in trilos-
tane-treated rats, suggesting a proconvulsant effect of the in-
crease in neurosteroid levels. However, this initial effect was 
not durable. Moreover, considering the seizure duration, the 
overall response to trilostane appeared to be more anticonvul-
sant than proconvulsant, because it was mainly characterized 
by reduction in duration of convulsive seizures. In particular, 
trilostane-treated rats presented with shorter stage 4 seizures 
for hours.
We have no simple explanation for the changes described 
in trilostane-treated rats. GABAergic neurons play a complex 
role in establishing seizure onset and duration. By optoge-
netically stimulating parvalbumin interneurons in epileptic 
mice, Lévesque and collaborators found that the seizure rate 
was reduced, but the seizure probability instead increased, in-
dicating that the enhanced GABA release from parvalbumin 
interneurons can paradoxically promote seizures.10 Although 
we have not evaluated these phenomena in our animals, the 
GABAergic tone could be expected to increase in trilos-
tane-treated animals, possibly reproducing a situation similar 
to that characterized by Lévesque and collaborators in their 
epileptic mice.
Neurosteroids are currently under investigation for their 
possible therapeutic effects in epilepsy and SE. Encouraging 
preclinical evidence for allopregnanolone and its 3β-methyl 
derivate ganaxolone, administered 30 minutes after SE onset, 
has been obtained in a mouse model based on tetramethy-
lenedisulfotetramine injection.11 For the same molecules, 
the positive findings were confirmed in the lithium-pilocar-
pine model of SE.12 Interestingly, additive properties were 
also described by combining ganaxolone with tiagabine or 
midazolam.13 This further evidence suggests that neuroste-
roids could be used in polytherapy to address SE. Not only 
allopregnanolone but also other neurosteroids could be can-
didates for this purpose, because both androstanediol and 
5α-dihydroprogesterone have displayed anticonvulsant ef-
fects.14,15 However, the use of neurosteroids could be limited 
in male subjects, who have appeared to be less sensitive than 
female subjects to the anticonvulsant properties of at least 
some of them.14
The use of trilostane to increase the availability of a 
variety of neurosteroids in the brain could be an alterna-
tive to the administration of a single steroid. Steroids are 
generally metabolized slowly and could afford longer pro-
tection than other endogenous anticonvulsant molecules, 
such as the peptides. For instance, in ovariectomized rats, 
the half-life of exogenously administered progesterone was 
1.21 ± 0.21 hours.16 Because we found a sixfold increase 
in progesterone levels in the brain, we hypothesized that 
this neurosteroid was more available during SE induction 
and possibly also in the period of convulsive seizures. 
Trilostane might have contributed to maintaining elevated 
brain neurosteroid levels, because its effects on the sup-
pression of cortisol production in dogs was shown to last 
up to 12  hours.5 This is because the reported half-life of 
trilostane is 8 hours. Although trilostane is reported to be 
specific for the adrenal cortex, we are not aware of any 
possible direct effect of this drug on the brain or, espe-
cially, whether this effect may appear because of dysfunc-
tion of the blood-brain barrier in the course of SE. This 
question must be addressed in future experiments aimed at 
establishing the time course of the changes in neurosteroid 
levels in cerebral tissue during SE. However, our findings 
suggest that the neurosteroids are able to modulate SE, pro-
viding that most of them are increased. It remains to be 
established whether similar effects could be observed if tri-
lostane is administered after the onset of SE, so as to assess 
the possible clinical use of this drug in the course of SE.
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